Expected, observed and relative paper scores from heterogeneous author-paper-citation networks

2019 ◽  
Vol 119 (2) ◽  
pp. 1275-1279
Author(s):  
Gangan Prathap
Design Issues ◽  
2020 ◽  
Vol 36 (1) ◽  
pp. 30-44
Author(s):  
Jonathan Lewis

This article reveals how citation networks can be used to understand and demonstrate the ways design serves to integrate other bodies of knowledge. Analysis focused on two corpuses of peer-reviewed journal articles, representing two bodies of knowledge. The first corpus consisted of 277 articles with the words “Design Thinking” in title. The second corpus contained 296 articles with the words “Network Science” in the title. Paper citation and document co-citation networks of individual and combined corpuses were analyzed. The overlap of paper citation networks was used to synthesize similarities, differences, and opportunities for further integration.


Author(s):  
Rogier De Langhe

Philosophical theories of scientific progress are typically disconnected from citation data because a citation to a paper does not necessarily justify the content of the cited paper. Citation data can however be used to test whether scientific contributions coevolve and as such discriminate indirectly between the two main theories of scientific progress: cumulative and non-cumulative progress. This chapter presents this novel approach. First, agent-based models are used to discover essential differences between both patterns of progress. The systematic exploration they allow of their respective entailments reveals four conflicting empirical predictions. These could in principle be tested against citation data, thus operationalizing two important philosophical conceptions of progress. The proposed approach relies heavily on two recent developments, the use of agent-based modeling in philosophy and the availability of vast citation datasets. The research program it suggests offers a unique opportunity to bridge the gap between descriptions of science and explanations of why it is successful.


Author(s):  
Mark Newman

This chapter describes models of the growth or formation of networks, with a particular focus on preferential attachment models. It starts with a discussion of the classic preferential attachment model for citation networks introduced by Price, including a complete derivation of the degree distribution in the limit of large network size. Subsequent sections introduce the Barabasi-Albert model and various generalized preferential attachment models, including models with addition or removal of extra nodes or edges and models with nonlinear preferential attachment. Also discussed are node copying models and models in which networks are formed by optimization processes, such as delivery networks or airline networks.


2021 ◽  
Vol 104 (1) ◽  
pp. 003685042110005
Author(s):  
Mingnan Cao ◽  
Li Wang ◽  
Lin Zhang ◽  
Jingli Duan

Drug-induced liver injury (DILI) is one of the common adverse drug reactions and the leading cause of drug development attritions, black box warnings, and post-marketing withdrawals. Current biomarkers are suboptimal in detecting DILI and predicting its outcome. This study aimed to quantitatively and qualitatively investigate the research trends on DILI biomarkers using bibliometric analysis. All relevant publications were extracted from the Web of Science database. An online analysis platform of literature metrology, bibliographic item co-occurrence matrix builder, and CiteSpace software were used to analyze the publication trends. CitNetExplorer was used to construct direct citation networks and VOSviewer was used to analyze the keywords and research hotspots. We found a total of 485 publications related to DILI biomarkers published from 1991 to 2020. Toxicological Sciences had been the most popular journal in this field over the past 30 years. The USA maintained a top position worldwide and provided a pivotal influence, followed by China. Among all the institutions, the University of Liverpool was regarded as a leader for research collaboration. Moreover, Professors Paul B. Watkins and Tsuyoshi Yokoi made great achievements in topic area. We analyzed the citation networks and keywords, therefore identified five and six research hotspot clusters, respectively. We considered the publication information regarding different countries/regions, organizations, authors, journals, et al. by summarizing the literature on DILI biomarkers over the past 30 years. Notably, the subject of DILI biomarkers is an active area of research. In addition, the investigation and discovery of novel promising biomarkers such as microRNAs, keratin18, and bile acids will be future developing hotspots.


Toxins ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 370
Author(s):  
Dirk Dressler ◽  
Lizhen Pan ◽  
Junhui Su ◽  
Fei Teng ◽  
Lingjing Jin

In 1997, lanbotulinumtoxinA (LAN) was introduced in China. It is now available in Asia, Latin America and Eastern Europe under various brand names including Hengli®, Lantox®, Prosigne®, Lanzox®, Redux®, Liftox®, HBTX-A and CBTX-A. The literature on LAN is mostly published in Chinese language, restricting its international accessibility. We, therefore, wanted to generate a complete English bibliography of all LAN publications and then use it for a comprehensive formalised literature review. Altogether, 379 LAN publications (322 in Chinese and 57 in English) were retrieved from PubMed and Science and Technology Paper Citation Database. Indications covered are motor (257), glandular (16), pain (32) and aesthetics (48). Topics are neurological (250), aesthetic (48), paediatric (38), ophthalmological (18), urological (9), methodological (6), gastroenterological (5), ear, nose and throat (4) and surgical (1). Seventy-one publications are randomised controlled trials, forty-one publications are interventional studies and observational studies, fifteen publications are case studies, eighteen publications are reviews, and two publications are guidelines. LAN publications cover all relevant topics of BT therapy throughout a period of more than 20 years. This constitutes a publication basis resembling those of other BT drugs. None of the LAN publications presents data contradictory to those generated with other BT type-A drugs. LAN seems to have a similar efficacy and safety features when compared to onabotulinumtoxinA using a 1:1 LAN– onabotulinumtoxinA conversion ratio. Large controlled multicentre studies will become necessary for LAN’s registrations in Europe and North America.


2020 ◽  
Vol 125 (1) ◽  
pp. 385-404
Author(s):  
Chakresh Kumar Singh ◽  
Demival Vasques Filho ◽  
Shivakumar Jolad ◽  
Dion R. J. O’Neale
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document